Blog

Michael Torres: This review is getting a lot of play

Photo from nature.com

May 22, 2024, 04:28

Michael Torres: This review is getting a lot of play

Michael Torres, PhD in Cancer Bio at UT Southwestern News, shared on X/Twitter:

“Homogeneous multi-payload antibody–drug conjugates | This review is getting a lot of play. Happy to see the ⁦CrossBridge Bio tech flagged as a ‘notable work demonstrating greater benefit compared to co-administration of the single ADC’.

Now all we need to do is leverage the great resources around such as David S. Hong, Martin Dietrich, Paolo Tarantino, MD Anderson Cancer Center and more to get this to patients as soon as we can!

It’s not lost on us that one of the authors is at flagship so wouldn’t be surprised…have they done an ADC co, yet?”

Source: Michael Torres/X

ADC Antibody drug conjugates cancer CrossBridge Bio David S. Hong Homogeneous multi-payload antibody Martin Dietrich MD Anderson Cancer Center Michael Torres OncoDaily Oncology Paolo Tarantino

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

Monica Bertagnolli is ending her tenure as NIH director

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

Special Coverage